HLA-DR antigen-negative acute myeloid leukemia
Meir Wetzler, Maria R. Baer(University of Maryland, Baltimore), Leslie E. Blumenson(Roswell Park Comprehensive Cancer Center), B K McElwain(Roswell Park Comprehensive Cancer Center), Maurice Barcos(Roswell Park Comprehensive Cancer Center), Carleton C. Stewart(University of Maryland, Baltimore), L. Ford(Roswell Park Comprehensive Cancer Center), Soldano Ferrone(Massachusetts General Hospital), James L. Slack(Memorial Sloan Kettering Cancer Center), Amir Mortazavi(The Ohio State University)
Cited by 78
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k